NCT00711243View on ClinicalTrials.gov

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 20, 2005

Primary Completion Date

December 15, 2008

Study Completion Date

February 25, 2011

Conditions
Gastric CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

docetaxel

Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

DRUG

fluorouracil

Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

DRUG

oxaliplatin

Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00711243 - Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | Biotech Hunter | Biotech Hunter